Search
Arcturus Therapeutics Holdings Inc
ARCTAdd to Watchlist
7.280USD
+0.390+5.66%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
206.92MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+5.66%
5 Days
+5.81%
1 Month
-9.45%
6 Months
+16.48%
Year to Date
+18.76%
1 Year
-47.17%
Key Figures
7.320Open
8.280High
1.91MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
6.70%Turnover Ratio
6.890Prev. Close
7.260Low
9.81MTurnover
LossP/E Static
1.08P/B
0.00%Div Yield TTM
-27.26%ROA
24.17052wk High
3.85Volume Ratio
-80.94MNet Profit
28.42MShares
-2.8315EPS TTM
2.37Beta
-37.01%ROE
5.85052wk Low
14.80%Amplitude
100.00%Gross Margin
206.92MMarket Cap
-3.15Reward/Risk
4.54%Risk Rate
TradingKey Stock Score of Arcturus Therapeutics Holdings Inc
Currency: USD Updated: 2026-07-02Key Insights
Arcturus Therapeutics Holdings Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 139 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.89.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Arcturus Therapeutics Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Arcturus Therapeutics Holdings Inc Highlights
StrengthsRisks
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Growing
The company is in a growing phase, with the latest annual income totaling USD 82.03M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 82.03M.
Overvalued
The company’s latest PE is -2.57, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 23.00M shares, decreasing 21.86% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 2.79M shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
19.889
Target Price
+188.66%
Upside Space
Arcturus Therapeutics Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Arcturus Therapeutics Holdings Inc Info
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Ticker SymbolARCT
CompanyArcturus Therapeutics Holdings Inc
CEOPayne (Joseph E)
Websitehttps://arcturusrx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Arcturus Therapeutics Holdings Inc (ARCT)?
The current price of Arcturus Therapeutics Holdings Inc (ARCT) is 7.28.
What is the symbol of Arcturus Therapeutics Holdings Inc?
The ticker symbol of Arcturus Therapeutics Holdings Inc is ARCT.
What is the 52-week high of Arcturus Therapeutics Holdings Inc?
The 52-week high of Arcturus Therapeutics Holdings Inc is 24.17.
What is the 52-week low of Arcturus Therapeutics Holdings Inc?
The 52-week low of Arcturus Therapeutics Holdings Inc is 5.85.
What is the market capitalization of Arcturus Therapeutics Holdings Inc?
The market capitalization of Arcturus Therapeutics Holdings Inc is 206.92M.
Is Arcturus Therapeutics Holdings Inc (ARCT) currently rated as Buy, Hold, or Sell?
According to analysts, Arcturus Therapeutics Holdings Inc (ARCT) has an overall rating of Buy, with a price target of 19.89.
What is the Earnings Per Share (EPS TTM) of Arcturus Therapeutics Holdings Inc (ARCT)?
The Earnings Per Share (EPS TTM) of Arcturus Therapeutics Holdings Inc (ARCT) is -2.40.